Skip to main content

Eli Lilly stock jumps 8% after Alzheimer’s treatment slows disease progression in major trial

After one year, nearly half of trial's participants showed no disease progression, says Lilly.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.